Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch
Immix Biopharma (NASDAQ:IMMX) appointed Michael Grabow as Chief Commercial Officer effective Nov 12, 2025 to lead U.S. commercialization and launch of NXC-201 in relapsed/refractory AL amyloidosis. The company highlighted Michael’s >25 years of commercialization experience and his role leading MODEYSO® go-to-market at Chimerix, which was acquired by Jazz for $935 million in 2025. Immix noted NXC-201 has received RMAT and Orphan Drug Designation from the FDA and positions a one-and-done approach for a disease with no currently approved FDA therapies.
Immix Biopharma (NASDAQ:IMMX) ha nominato Michael Grabow come Chief Commercial Officer, con effetto dal 12 novembre 2025, per guidare la commercializzazione statunitense e il lancio di NXC-201 nell'amyloidosi AL ricorrente/refrattaria. L'azienda ha evidenziato oltre 25 anni di esperienza di commercializzazione di Michael e il suo ruolo nel guidare il go-to-market di MODEYSO® presso Chimerix, azienda acquisita da Jazz per 935 milioni di dollari nel 2025. Immix ha osservato che NXC-201 ha ricevuto RMAT e Orphan Drug Designation dalla FDA e posiziona un approccio one-and-done per una malattia senza terapie FDA attualmente approvate.
Immix Biopharma (NASDAQ:IMMX) designó a Michael Grabow como Director Comercial, con efecto el 12 de noviembre de 2025, para liderar la comercialización en Estados Unidos y el lanzamiento de NXC-201 en la amiloidosis AL recidivante/refractaria. La empresa destacó más de 25 años de experiencia de Michael en la comercialización y su papel al liderar el go-to-market de MODEYSO® en Chimerix, empresa adquirida por Jazz por 935 millones de dólares en 2025. Immix señaló que NXC-201 ha recibido RMAT y Orphan Drug Designation de la FDA y posiciona un enfoque de una sola dosis para una enfermedad que actualmente no tiene terapias aprobadas por la FDA.
Immix Biopharma (NASDAQ:IMMX)는 2025년 11월 12일부로 Michael Grabow를 최고상업책임자(COO)로 임명하여 미국 내 상업화 및 relapsed/refractory AL 아밀로이드증의 NXC-201 출시를 주도합니다. 회사는 Michael의 25년이 넘는 상업화 경험과 Chimerix에서 MODEYSO®의 출시 전략을 주도한 그의 역할을 강조했으며, Chimerix는 2025년에 Jazz에 9억 3500만 달러에 인수되었습니다. Immix는 NXC-201이 FDA로부터 RMAT와 Orphan Drug Designation을 받았고 현재 FDA가 승인한 치료제가 없는 질병에 대해 일회 투여 접근 방식을 제시한다고 밝혔습니다.
Immix Biopharma (NASDAQ:IMMX) a nommé Michael Grabow au poste de Chief Commercial Officer, à compter du 12 novembre 2025, pour diriger la commercialisation américaine et le lancement de NXC-201 dans l’amylose AL récidivante/réfractaire. L’entreprise a souligné les plus de 25 années d’expérience de Michael en matière de commercialisation et son rôle dans la mise sur le marché de MODEYSO® chez Chimerix, acquise par Jazz pour 935 millions de dollars en 2025. Immix a noté que NXC-201 a reçu le RMAT et la designation Orphan Drug de la FDA et propose une approche d’une dose unique pour une maladie sans thérapies approuvées par la FDA à ce jour.
Immix Biopharma (NASDAQ:IMMX) ernannte Michael Grabow zum Chief Commercial Officer, wirksam ab dem 12. November 2025, um die US-Commercialisierung und den Markteintritt von NXC-201 bei der AL-Amyloidose im rezidivierenden/refraktären Stadium zu leiten. Das Unternehmen hob Michaels mehr als 25 Jahre Erfahrung in der Vermarktung hervor und seine Rolle bei der Einführung von MODEYSO® bei Chimerix, das 2025 von Jazz für 935 Millionen Dollar übernommen wurde. Immix stellte fest, dass NXC-201 RMAT und die Orphan Drug Designation von der FDA erhalten hat und einen One-and-Done-Ansatz für eine Krankheit mit derzeit keinen von der FDA genehmigten Therapien bietet.
عَيَّنت Immix Biopharma (ناسداك: IMMX) السيد مايكل جابو كـ Chief Commercial Officer، اعتبارًا من 12 نوفمبر 2025، لقيادة التسويق في الولايات المتحدة وإطلاق NXC-201 في داء أميلويد AL الانتكاسي/المقاوم. أشارت الشركة إلى أكثر من 25 عامًا من خبرة مايكل في التسويق ودوره في قيادة استراتيجية go-to-market لـ MODEYSO® في Chimerix، التي استحوذ Jazz عليها مقابل 935 مليون دولار في 2025. وأشارت Immix إلى أن NXC-201 تلقّى RMAT وDesignación Orphan Drug من FDA ويقدم نهج جرعة واحدة لحالة مرضية لا توجد لها علاجات معتمدة من FDA في الوقت الحالي.
- RMAT and Orphan Drug Designation awarded by FDA
- 25+ years of commercialization experience for new CCO
- Led MODEYSO® launch; Chimerix acquisition for $935M
- No currently approved FDA therapies for relapsed/refractory AL amyloidosis
- NXC-201 not yet approved (commercial launch contingent on future approval)
- Former Chimerix (CMRX, acquired by Jazz for
- Rare disease commercial veteran Mr. Grabow to lead Immix’s U.S. launch and commercial buildout for NXC-201 in relapsed/refractory AL Amyloidosis, a serious, rare, blood disease with no currently approved FDA therapies -
LOS ANGELES, CA, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced the appointment of former Chimerix (CMRX, acquired by Jazz for
“AL amyloidosis is a devastating disease that causes organ failure and death. We believe that NXC-201 is uniquely positioned to save lives, eliminating the high unmet need in relapsed/refractory AL Amyloidosis,” said Ilya Rachman, M.D., Ph.D., Chief Executive Officer of Immix Biopharma. Gabriel Morris, Chief Financial Officer of Immix Biopharma, added, “Michael’s appointment will accelerate deployment of NXC-201’s one-and-done approach, which we believe will be the first approved therapeutic in relapsed/refractory AL Amyloidosis.”
Michael Grabow added, “Leading the NXC-201 launch is an especially exciting opportunity. Clinical results are compelling, Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug Designation (ODD) have been awarded by the FDA, and NXC-201 promises to transform the standard of care for a deadly disease with no approved therapies. I am thrilled to work with the Immix team as we elevate to a commercially focused company.”
Michael has more than 25 years of biopharmaceutical commercialization experience. Prior to joining Immix, Michael was Head of Commercial Operations at Chimerix, Inc., where he led Go-To-Market Strategy and Launch of orphan drug MODEYSO® (dordaviprone), a first-in-disease therapy that was granted accelerated approval in 2025 for H3 K27M-mutant diffuse midline glioma, an ultra-rare and aggressive brain tumor that, prior to MODEYSO®, previously had no FDA-approved therapies. MODEYSO® was granted accelerated approval based on an integrated efficacy analysis of 50 patients, selected from five open-label studies (Jazz Pharmaceuticals acquired Chimerix for
About AL Amyloidosis
AL amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead continuously produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death.
The number of patients in the U.S. with relapsed/refractory AL Amyloidosis is estimated to be growing at
The Amyloidosis market was
About NXC-201
NXC-201 is a sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy with a “digital filter” that filters out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 has been awarded Regenerative Medicine Advanced Therapy (RMAT) by the FDA, and Orphan Drug Designation (ODD) by the US FDA and in the EU by the EMA.
About Immix Biopharma, Inc.
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is the global leader in relapsed/refractory AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a “digital filter” that filters out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a registrational design. NXC-201 has been awarded Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA. Learn more at www.immixbio.com and www.BeProactiveInAL.com.
Forward Looking Statements
This press release contains forward-looking statements regarding Immix Biopharma, Inc., its results of operations, prospects, future business plans and operations and the matters discussed above, including, but not limited to, the potential benefits of our product candidate CAR-T NXC-201 and the timing and results related to clinical trials. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Forward-looking statements also include, but are not limited to, our plans, objectives, expectations and intentions and other statements that contain words such as “expects”, “contemplates”, “anticipates”, “plans”, “intends”, “believes”, “estimates”, “potential”, and variations of such words or similar expressions that convey the uncertainty of future events or outcomes, or that do not relate to historical matters. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) the risk that the further data from the ongoing Phase 1/2 clinical trials for CAR-T NXC-201 will not be favorably consistent with the data readouts to date, (ii) the risk that the Company may not be able to continue the NEXICART-2 multi-site U.S. Phase 1/2 clinical trial; (iii) the risk that the Company may not be able to advance to registration-enabling studies for CAR-T NXC-201 or other product candidates, (iv) that success in early phases of pre-clinical and clinicals trials do not ensure later clinical trials will be successful; (v) that no drug product developed by the Company has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (vi) the risk that the Company may not be able to obtain additional working capital with which to continue the clinical trials for CAR-T NXC-201, or advance to the initiation of registration-enabling studies, for such product candidates as and when needed and (vii) those other risks disclosed in the section “Risk Factors” included in the Company’s Annual Report on Form 10-K filed with the SEC on March 25, 2025 and other periodic reports subsequently filed with the Securities and Exchange Commission. These reports are available at www.sec.gov. Immix Biopharma cautions that the foregoing list of important factors is not complete. Immix Biopharma cautions readers not to place undue reliance on any forward-looking statements. Immix Biopharma does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.
Contacts
Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com
Company Contact
irteam@immixbio.com
FAQ
What will Michael Grabow do as Chief Commercial Officer of IMMX?
What regulatory designations has NXC-201 received for IMMX (IMMX)?
How does Michael Grabow’s experience relate to IMMX’s NXC-201 launch?
Does relapsed/refractory AL amyloidosis have any FDA-approved therapies now?
Will NXC-201 immediately reach patients after this appointment?
